National Practice Patterns and Outcomes for T4b Urothelial Cancer of the Bladder

被引:21
作者
Haque, Waqar [1 ]
Verma, Vivek [2 ]
Butler, E. Brian [3 ]
Teh, Bin S. [3 ]
机构
[1] Greater Houston Phys Med Assoc, Dept Radiat Oncol, Houston, TX USA
[2] Univ Nebraska Med Ctr, Dept Radiat Oncol, Omaha, NE USA
[3] Houston Methodist Hosp, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
Bladder cancer; Chemoradiation; Chemotherapy; Cystectomy; Radiation therapy; RADICAL CYSTECTOMY; DATA-BASE; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; SURVIVAL; CARCINOMA; CARE; THERAPY;
D O I
10.1016/j.clgc.2017.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The National Cancer Data Base was queried (2004-2013) for patients diagnosed with T4b bladder cancer. A total of 896 patients were observed. Patients treated with definitive chemoradiation or radical cystectomy were observed to have the highest overall survival. Purpose: Management of cT4b bladder cancer is poorly defined; national guidelines recommend chemotherapy (CT) alone or chemoradiation (CRT). Using a large, contemporary dataset, we evaluated national practice patterns as well as associated outcomes, especially with respect to radical cystectomy (RC) and CRT versus CT alone. Methods: The National Cancer Data Base was queried (2004-2013) for patients diagnosed with cT4bN0-3M0 bladder cancer. Patients were divided into 5 treatment groups: CT alone, CRT, RC (with/without CT/radiotherapy [RT]), other treatment (subtherapeutic RT with/without CT), or no treatment. Statistics included multivariable logistic regression to determine factors predictive of observation, Kaplan-Meier analysis to evaluate overall survival (OS), and Cox proportional hazards modeling to determine variables associated with OS. Results: Of 896 total patients, 185 (20.6%) underwent CT alone, 80 (8.9%) CRT, 161 (18.9%) RC, 221 (24.7%) other treatments, and 249 (27.8%) observation. Differences in treatment paradigms were appreciated based on age, gender, nodal status, insurance, and facility-related parameters. Observation yielded a median OS of 3.7 months, lower than CT alone (P < .001). As compared with the latter, CRT was associated with higher OS (10.5 vs. 12.1 months, P = .004). RC-based treatment displayed the numerically highest OS (14.2 months) and was statistically similar to CRT (P = .676). Treatment with any modality independently predicted for superior OS over observation. Conclusions: In the largest study of its kind, a surprisingly high proportion of patients underwent observation. CRT is associated with higher survival over CT alone, and carefully selected patients undergoing RC may experience prolonged survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / +
页数:9
相关论文
共 50 条
  • [41] Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands
    Reesink, Daan J.
    van de Garde, Ewoudt M. W.
    van der Nat, Paul
    Somford, Diederik M.
    Los, Maartje
    Horenblas, Simon
    van Melick, Harm H. E.
    WORLD JOURNAL OF UROLOGY, 2022, 40 (06) : 1469 - 1479
  • [42] Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)
    Doshi, Gurjyot K.
    Bhanegaonkar, Abhijeet
    Kearney, Mairead
    Bharmal, Murtuza
    Cislo, Paul
    Kim, Ruth
    Boyd, Marley
    Aguilar, Kathleen M.
    Phatak, Hemant
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 645 - 656
  • [43] En bloc resection of a T4B stage cancer of the hepatic flexure of the colon invading the liver, gall bladder, and pancreas/duodenum: A case report
    Meng, Linghou
    Huang, Zigao
    Liu, Jungang
    Lai, Hao
    Zuo, Hongqun
    Liao, Jiankun
    Lin, Yuan
    Tang, Weizhong
    Mo, Xianwei
    CLINICAL CASE REPORTS, 2020, 8 (12): : 3523 - 3527
  • [44] Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer
    Zirakzadeh, A. Ali
    Kinn, Johan
    Krantz, David
    Rosenblatt, Robert
    Winerdal, Malin E.
    Hu, Jin
    Hartana, Ciputra Adijaya
    Lundgren, Christian
    Bergman, Emma Ahlen
    Johansson, Markus
    Holmstrom, Benny
    Hansson, Johan
    Sidikii, Alexander
    Vasko, Janos
    Marits, Per
    Sherif, Amir
    Winqvist, Ola
    CLINICAL IMMUNOLOGY, 2017, 176 : 63 - 70
  • [45] Practice patterns and survival outcomes of intracranial germinoma: an analysis of the National Cancer Database
    Wang, Wei Gang
    Ye, Hong
    Chinnaiyan, Prakash
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (01) : 77 - 82
  • [46] Practice patterns and survival outcomes of intracranial germinoma: an analysis of the National Cancer Database
    Wei Gang Wang
    Hong Ye
    Prakash Chinnaiyan
    Journal of Neuro-Oncology, 2018, 137 : 77 - 82
  • [47] Survival outcomes in node-positive non-metastatic bladder cancer: An analysis of the national cancer database
    Elbakry, Amr A.
    Trump, Tyler
    Ferari, Christopher
    Mattes, Malcom D.
    Luchey, Adam
    ARAB JOURNAL OF UROLOGY, 2022, 20 (04) : 175 - 181
  • [48] Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database
    Darwish, Christina
    Sparks, Andrew
    Amdur, Richard
    Reddy, Akshay
    Whalen, Michael
    UROLOGY, 2020, 146 : 168 - 175
  • [49] Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer
    Porter, Michael P.
    Kerrigan, Matthew C.
    Donato, Bonnie M. K.
    Ramsey, Scott D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (03) : 252 - 258
  • [50] Use of radiotherapy for bladder cancer: A population-based study of evolving referral and practice patterns
    Wei, Xuejiao
    Siemens, D. Robert
    Mackillop, William J.
    Booth, Christopher M.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (04): : 92 - +